drugset / Trial / NCT04409002
Niraparib + Dostarlimab + RT in Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
This research is being done to see how the combination of dostarlimab, niraparib, and radiation therapy works in controlling metastatic pancreatic cancer.
Timeline
- Start
- 2020-07-23
- Primary completion
- 2022-01-19
- Completion
- 2022-02-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dostarlimab | Monoclonal antibody | — | Intravenous |
| Subject | Niraparib | Small molecule | — | Oral |